secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001493152-25-023988
Event type: m_and_a
Sentiment:  positive
Materiality: 0.45
Item codes: 2.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow completes Melt acquisition for ~$4.3M cash; outlines MELT-300 NDA timeline
--------------------------------------------------------------------------------

- Paid ~$4.3M cash at closing for remaining Melt equity; contingent milestone payments unchanged.
- Acquires Melt pipeline: MELT-300 (Phase 3, SPA), MELT-210, MELT-400; expands into procedural sedation.
- Next steps for MELT-300: PK studies, NDA submission H1 2027, potential approval H1 2028, launch H2 2028.
- MELT-300 is a sublingual midazolam/ketamine formulation; could be first FDA-approved non-opioid non-IV sedation.
- Integration of Melt into Harrow's operations; leveraging MKO Melt network for commercial readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225023988/0001493152-25-023988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225023988/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-023988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer